indic
john
lawrenc
letter
infecti
diseas
newslett
undergo
mark
chang
editori
direct
format
wish
dr
paul
hoeprich
well
endeavor
whatev
assist
give
energi
new
direct
first
issu
idn
thought
would
focu
area
believ
high
activ
come
year
culmin
definit
inform
chang
concept
diagnost
practic
therapeut
activ
number
caus
suggest
basi
occurr
acquiredimmunedefici
syndrom
aid
initi
believ
intens
exposur
cytomagoloviru
somehow
influenc
lymphocyt
function
produc
aberr
immunolog
find
aid
premis
held
search
continu
possibl
etiolog
agent
suggest
made
immunolog
aberr
may
secondari
drug
use
thesi
also
sustain
search
viral
caus
end
cytomegaloviru
hypothesi
sever
observ
note
unusu
morpholog
chang
sucha
vesicular
rosett
lymph
node
lymphoid
cell
tubular
reticular
structur
within
cistern
smooth
endoplasm
reticula
lymphocyt
patient
one
hypothesi
explain
occurr
viral
infect
lymphocyt
studi
hemophiliac
receiv
factor
viii
therapi
butnot
form
replac
suggest
transmiss
agent
possibl
factor
viii
concentr
result
immunolog
aberr
unlik
seen
aid
investig
suggest
possibl
link
aid
human
tcell
leukemia
viru
htlv
agent
associ
previous
rare
type
human
cancer
number
line
evid
suggest
htlva
possibl
etiolog
agent
first
htlv
preval
caribbean
area
africa
area
occurr
aid
popul
htlv
agent
affect
tcell
select
basi
sinc
primari
aid
defect
appear
tlymphocyt
hypothes
agent
primarili
infect
cell
might
logic
candid
htlv
also
appear
spread
intim
contact
prerequisit
theori
aid
transmissior
one
analog
htlv
caus
cancer
immunosuppress
true
number
leukemia
virus
anim
htlv
retroviru
rna
core
transcrib
viral
dna
found
cell
patient
aid
healthi
homosexu
male
control
infecti
htlv
prticl
isol
one
patient
tcell
two
patient
evid
viral
dna
viru
identifi
htlvi
appar
common
type
among
isolar
viru
antibodi
htlv
found
proport
aid
patient
rare
among
control
individu
featur
htlv
parallel
featur
aid
give
rise
sceptic
whether
agent
fact
caus
aid
simpli
one
mani
agent
aid
patient
becom
infect
recent
suggest
made
cyclosporin
produc
infect
saprophyt
fungu
thermoacu
crustaceu
may
caus
aid
problem
postul
infecti
agent
immunodefici
part
aid
may
predispos
infect
wide
varieti
opportunist
agent
result
one
certain
isol
agent
identif
host
respons
anyway
reflect
etiolog
guess
result
discoveri
precis
caus
aid
mode
transmiss
legionella
stori
preced
abl
better
understand
epidemiolog
disord
presum
lesser
form
diseas
may
occur
lyme
diseas
acut
infiammatori
disord
character
specif
skin
rash
erythema
chronicum
migran
puzzl
time
steer
benach
other
discov
spriochet
patient
ixod
sp
tick
te
spriochet
uniqu
evok
antibodi
respons
measur
specif
igm
igg
expect
definit
infect
agent
includ
perhap
milder
form
diseas
even
asymptomat
infect
one
excit
find
report
identif
plemorph
gram
neg
bacteria
vast
major
lymph
node
specimen
patient
cat
scratch
diseas
caus
diseas
extrem
elus
therefor
difficult
diagnos
certainti
bacteria
either
isol
otherwis
identifi
host
respons
propel
cat
scratch
diseas
medic
odditi
well
character
infect
discov
new
infecti
diseas
caus
elud
us
thu
far
like
progress
infecti
diseas
past
decad
either
newli
identifi
seem
aris
de
novo
continu
obvious
redict
thenatur
think
physician
alert
pfssibil
odd
patient
see
conform
textbook
descript
may
herald
case
new
disord
caus
disord
kawaski
diseas
may
discov
year
one
intrigu
find
past
sever
decad
discoveri
genet
basi
immun
respons
infer
suscept
infecti
diseas
work
care
bred
anim
led
segreg
specif
factor
determin
genet
respons
genet
suscept
inform
partial
translat
human
experi
associ
certain
white
cell
type
reflect
genet
characterist
specif
inflammatori
disord
abil
respond
immunolog
certain
antigen
appear
relat
least
part
genet
makeup
individu
relat
certain
gene
loci
look
forward
definit
relationship
may
help
answer
sever
puzzl
question
confront
clinician
child
develop
enceph
epsteinbarr
viru
one
child
die
overwhelm
bacteremia
wherea
major
individu
polioviru
produc
paralysi
certain
individu
wherea
vast
major
expos
infect
individu
either
asymptomat
infect
nonparalyt
ill
question
plagu
us
vagu
relat
patient
constitut
germ
plasm
believ
threshold
discov
characterist
molecular
level
pathogenesi
cancer
appear
exteremli
complex
matter
discoveri
oncogen
interrelationship
environmentai
influenc
offer
hope
may
understand
complex
interact
infect
specif
agent
immunolog
respons
agent
immunosupt
pression
malign
transform
among
mani
challeng
confront
clinician
deal
infecti
diseas
segreg
individu
infect
atyp
mycobacteria
caus
skin
lymph
node
pulmonari
infect
year
ago
avail
skin
test
materi
thought
specif
enough
help
us
sort
individu
infect
atyp
mycobacteria
infect
past
experi
mycobacterium
tuberculosi
mate
remov
use
question
specif
yet
return
gener
use
belief
better
diagnost
method
area
possibl
releas
skin
test
antigen
hich
may
greaater
specif
use
past
one
breakthrough
anticip
reason
expect
develop
rapid
serolog
diagnost
test
sort
mani
virus
produc
gastrointestin
infect
rotavirus
prove
pathfind
regard
first
detect
sole
morpholog
appear
electronmicroscopi
stool
specimen
test
rapidli
yield
ria
elisa
identif
readili
avail
mani
diagnost
laboratori
suspect
e
continu
refin
diagnost
test
rotaviru
infect
anticip
agent
parvovirus
coronaviru
ether
masi
yield
similar
techniqu
develop
enzymelink
immunosorb
assay
eliea
promis
greatli
alter
diagnost
method
capabl
adapt
measur
either
antigen
antibod
respons
techniqu
offer
routin
icrobiolog
laboratori
opportu
iti
fairli
specif
highli
sensit
test
routin
detect
wide
varieti
antigen
mani
way
obviat
necess
routin
microbiolog
procedur
replac
cumber
one
detect
small
amount
antigen
antibodi
adapt
test
increas
number
infecti
igent
offer
promis
may
find
routin
laboratori
equip
make
diagnos
rapidli
greater
precis
sensit
ever
anticip
wider
use
latex
fixat
test
identif
bacteri
antigen
test
prove
extrem
use
detect
haemophilu
influenza
antigen
simpl
perform
requir
elabor
setup
ecessari
counterimmunoelectrophoresi
requir
elabor
skill
part
technic
staff
like
test
may
adapt
antigen
commonli
seek
therapeut
anticip
continu
see
third
gener
cephalosporin
enter
unit
state
market
task
much
learn
use
learn
one
use
clear
earli
experi
moxalactam
drug
seldom
substitut
standard
form
therapi
place
resist
infect
certan
clinic
circumst
see
advent
new
gener
cephalosporin
heavi
promot
plethora
clinic
studi
look
forward
complet
public
third
cooper
neonat
mening
therapeut
studi
head
georg
mccracken
anticip
demonstr
combin
ampicillin
moxalactam
good
better
combin
ampicillin
amikacin
one
hope
dr
mccracken
colleagu
innovativebi
fourth
clinic
trial
attempt
find
therapeut
formula
reduc
morbid
mortal
current
regimen
one
excit
aspect
therapeut
research
develop
newer
antivir
agent
year
practition
plagu
increas
recognit
viral
caus
varieti
diseas
improv
method
diagnosi
includ
rapid
identif
mani
virus
possibl
inabl
significantli
influenc
cours
morbid
mortal
associ
infect
cours
difficulti
effect
antivir
treatment
usual
involv
interfer
viral
replic
close
parallel
physiolog
process
normal
cell
result
toxic
sever
limit
factor
even
agent
therapeut
effect
agent
surviv
dilemma
becom
use
clinic
practic
recent
acyclovir
herp
viru
infect
great
promis
topic
oral
form
antivir
agent
may
find
nich
therapeut
armamentarium
one
excit
find
came
close
report
ribvarin
success
treatment
respiratori
syncytialviru
infect
promis
preliminari
find
suggest
look
forward
newer
use
antivir
